Gemcitabine and Topotecan in Treating Patients With Recurrent or Persistent Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

Completed · Phase 2

Conditions studied: Fallopian Tube Cancer, Ovarian Cancer, Peritoneal Cavity Cancer

In brief

RATIONALE: Drugs used in chemotherapy, such as gemcitabine and topotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells. PURPOSE: This phase II trial is studying how well giving gemcitabine together with topotecan works in treating patients with recurrent or persistent ovarian, fallopian tube, or primary peritoneal cavity cancer.

Key facts

Study ID

NCT00217555

Run by

Fred Hutchinson Cancer Center

Starts

2002-07-01

Last updated by the study team

2010-09-21

Who can join

Age: 18 and older. Sex: female. Healthy volunteers: not accepted.

Where it is running

• University of Washington School of Medicine — Seattle, Washington, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.